|From: stormcat (Rep: 440)||Date: 07/10/2018 13:32|
|Forum: Pinks and BB - Msg #127745 - List ICOTF msgs ||Thread #674020289 (Rec: 0) |
|in a few .135 could be a huge winner soon on this news...|
ICO THERAPEUTICS I
Symbol U : ICOTF
Recent Sedar Documents
iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study
2018-06-27 08:00 ET - News Release
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive primary end point in its Phase 1 clinical study. The study met its primary endpoint of safety and tolerability of iCo-019 (Oral Amp B) following oral administration of single ascending doses (4 dose levels) in healthy subjects. There were no serious adverse events (SAEs) and no drug-related adverse events (AEs) in either of the four study cohorts. All drug doses were well tolerated, including the highest dose of 800 mg, with no indication of kidney toxicity. "This is a very promising result for our future efficacy studies with oral Amphotericin B" stated Dr. Peter Hnik, CMO of iCo Therapeutics.
"We are pleased to report a positive primary endpoint related to our 32 subject Phase 1 clinical study" stated Andrew Rae, President and CEO of iCo Therapeutics Inc. "No patients experienced drug-related adverse or serious adverse events in our Phase 1 clinical study and we believe this allows us to claim leadership in the race towards developing an oral Amphotericin B drug." Mr. Rae also stated, "iCo Management waits with anticipation important and material pharmacokinetic data in the coming weeks."
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.